Search

everythinglearnresearchcommunity

for

Search:↓

RU58841's legitimacy and sourcing concerns. Users suggest caution and recommend trusted sources over platforms like Amazon.

A user is using homemade topical spironolactone for androgenetic alopecia and is unsure about its effectiveness due to concurrent telogen shedding. They are seeking advice on others' experiences with homemade topical spironolactone.

A female user has experienced severe hair shedding since stopping birth control in late 2022, diagnosed as telogen effluvium with no signs of androgenetic alopecia. Despite healthy living and optimal bloodwork, she continues to shed hair daily but also sees significant regrowth.

A user's two month update on their hair loss journey and the treatments they are trying, which include exosome injections, minoxidil, finasteride, and RU58841.

Exploring different treatments for hair loss, such as cosmeRNA and HMI-115 which are small interference messenger RNA that inhibits the DHT receptor and an antibody that binds to the prolactin (PRL) receptor respectively; and researching mechanism and environment of hyperresponders.

The conversation discusses using P5P (Vitamin B6) supplements to reduce elevated Prolactin levels and concerns about its potential effect on increasing DHT levels. The user is not currently using finasteride or any anti-androgens.

The conversation discusses switching from RU58841 to pyrilutamide for hair loss treatment, with users generally recommending staying on RU58841 if it is effective. RU58841 is sourced from GeneTherica, which ships worldwide.

Kintor Pharma completed a successful Phase II clinical trial for KX-826, a treatment for androgenetic alopecia. KX-826 is similar to finasteride with minor side effects and is more backed than Cosmerna.

The conversation is about treatments for androgenetic alopecia, focusing on hyperresponders. Treatments include Minoxidil, finasteride, RU58841, leg training, and cold therapy.

Exosomes are discussed as a new hair loss treatment, but skepticism is expressed about their effectiveness. Other treatments mentioned include Minoxidil, finasteride, and RU58841.

Exosome Therapy for hair loss, including its results and cost. The discussion also touches on the various serums used in this therapy.

Chinese company gets green light for Pyrilutamide Phase II trial for androgenetic alopecia. Androgen receptors downregulate in androgen deficient environments.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

Fatty acid metabolic signaling can activate epithelial stem cells for hair regeneration. Oleic and palmitoleic acids showed the best results, but practical application on humans remains uncertain.

Regenera Activa and exosome therapy are discussed for hair loss treatment, focusing on their effectiveness for regrowth, thickening, or reducing shedding. Users are seeking experiences and results from these treatments.

RU58841 is not recommended for use around children due to potential exposure risks. Alternatives like CB-03-01 might be considered, but further research is advised.

Topilutamide is a potential hair loss treatment between Clascoterone and RU58841. Users discuss finding Topilutamide powder and its possible benefits for those who can't afford or tolerate other treatments.

The conversation is about a user expressing concerns over the safety of a new drug called Pyrilutamide (also known as KX-826) for hair loss. The user will only trust the drug if it's permitted by EU regulations and sold by a reputable company.

RU-58642 is a powerful anti-androgen that was not developed further, possibly due to safety concerns or financial reasons. RU58841 is a topical alternative, but it is less effective than finasteride and dutasteride, and its long-term effects are not well-studied.

Pyrilutamide is officially available for purchase, and users suggest Fluridil as an alternative topical anti-androgen. Some users report positive results with pyrilutamide from Koshine.

Hair loss discussion includes treatments Min, Fin, and RU. Kintor's KX-826 Phase 2 data release delayed to September due to COVID.

Anageninc stopping the sale of Pyrilutamide due to a cease and desist order from Kintor, with some speculating that it was either a hoax or subpar product.

The user has been using oral minoxidil and dutasteride for hair loss without success and is considering adding topical 17α-estradiol, Pyrilutamide, Clascoterone, or cetirizine. They have confirmed low serum DHT levels and are exploring additional treatments due to genetic sensitivity to DHT and prostaglandin D2.

The conversation discusses the absorption and effectiveness of PG-free versus PG versions of RU58841, with some users believing PG improves efficacy while others see no difference. Concerns about RU58841's potential side effects on the endocrine system are also mentioned, with one user considering switching to pyrilutamide.

Pyrilutamide is an experimental hair loss treatment, with users discussing its availability and cost from sources like Anagen Inc, Actifolic, and MinoxidilMax. Some users express concerns about product authenticity and suggest waiting for further trial results to assess its safety and effectiveness.

Winlevi (clascoterone) is discussed as a treatment for hormonal acne and seborrheic dermatitis due to its ability to block DHT and regulate sebum production. The post suggests that Winlevi could offer a novel approach for managing seborrheic dermatitis.

A 22-year-old with high estradiol levels is considering starting finasteride for hair loss. They have an upcoming endocrinologist appointment to discuss whether they should proceed with the treatment.

The conversation is about whether castor oil can be effectively used alone after microneedling without a penetration enhancer like DMSO or ethanol. The user believes microneedling-induced wounds might be enough for absorption.

RU58841 should be refrigerated. The KB Solution is more effective at delivering RU58841 to the scalp.

Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.